(reported by the Company)
No items found
Dimerix Bioscience is a public unlisted clinical stage drug discovery and development company, based in Melbourne. Dimerix’s lead clinical program is a Phase 2 study in Chronic Kidney Disease, DMX-200. This study has repurposing of existing molecules at its core, and upon successful results from this study, Dimerix intends to pursue the pathway of registration of a product for an orphan indication. The study has been initiated at the Austin Hospital under the supervision of Professor Power, and is currently recruiting patients.
|Category:||Health & biotech|
|ASX Listing Code (if applicable):|
|Year of Commencement:||2004|
Dimerix Bioscience Limited
|State:||Victoria, Western Australia|